As filed with the U.S. Securities and Exchange Commission on February 6, 2026 Registration No. 333-292260 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 3842 86-1369123 Approximate date of commencement of proposed sale to the p ...

As filed with the U.S. Securities and Exchange Commission on February 6, 2026 Registration No. 333-292260 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear Parkw ...

Core Viewpoint - Envoy Medical, a hearing health company, is set to participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026, highlighting its commitment to innovation in hearing solutions [1]. Group 1: Company Overview - Envoy Medical (NASDAQ: COCH) specializes in innovative technologies for hearing loss, offering fully implanted devices such as the Esteem® active middle ear implant, available in the U.S. since 2010, and the investigational Acclaim® cochlear implant [2]. Group 2: Event Details - The Small Cap Growth Virtual Investor Conference will take place on February 5, 2026, at 10:00 A.M. ET, featuring a presentation followed by a real-time Q&A session for investors [1]. - A recording of the event will be accessible on Envoy's Investor Relations website for those unable to attend the live session [1].

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- (State or other jurisdiction of incorporation or organization) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

Core Insights - Envoy Medical will host a fireside chat featuring CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim cochlear implant, on December 11, 2025, at 4:30 P.M. ET [1][2] Company Overview - Envoy Medical, listed on NASDAQ as COCH, is a hearing health company focused on innovative technologies for hearing loss, including fully implanted devices like the Esteem active middle ear implant and the investigational Acclaim cochlear implant [3][4] - The Acclaim cochlear implant is designed to address severe to profound sensorineural hearing loss and has received Breakthrough Device Designation from the FDA in 2019 [5] Product Details - The Acclaim cochlear implant utilizes a sensor that leverages the natural anatomy of the ear to capture sound, distinguishing it as a first-of-its-kind hearing device [4] - The Esteem fully implanted active middle ear implant is the only FDA-approved device for adults with moderate to severe sensorineural hearing loss, providing continuous hearing without the need for external components [7]

Core Viewpoint - Envoy Medical, Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance and Outlook - The upgrade reflects an improvement in Envoy Medical's underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - For the fiscal year ending December 2025, Envoy Medical is expected to earn -$1.20 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 4.3% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Envoy Medical in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

As filed with the U.S. Securities and Exchange Commission on December 1, 2025. Registration No. 333-290927 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3842 86-1369123 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

As filed with the U.S. Securities and Exchange Commission on December 1, 2025. Registration No. 333-290927 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3842 86-1369123 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

Core Insights - Envoy Medical has secured a new U.S. patent for an innovative cochlear implant system that features a removable earplug sensor and an implanted battery, reinforcing its leadership in next-generation cochlear implant technology [1][2][3] Company Developments - The newly granted patent, titled "Combination Implant System with Removable Earplug Sensor and Implanted Battery," enhances Envoy Medical's intellectual property portfolio and covers systems that include an implantable subsystem with a stimulator and rechargeable energy storage [2][3] - The patent supports the company's long-term innovation strategy and aims to protect future advancements in implanted technologies, not just current devices [3] - Envoy Medical is making positive progress in its pivotal Acclaim® Cochlear Implant clinical trial, which has received Breakthrough Device Designation from the FDA in 2019 [3][4][8] Product Information - The Acclaim Cochlear Implant is designed for individuals with severe to profound sensorineural hearing loss and utilizes a sensor that leverages the natural anatomy of the ear instead of a microphone [7][8] - The Esteem® fully implanted active middle ear implant is another innovative product from Envoy Medical, which has been commercially available in the U.S. since 2010 and allows for continuous hearing without external components [5][9]